Search research articles
Contact Us
Filters
Showing results (81-90 of 323) with videos related to
Page
of 33
Sort By:
Plos One
|
April 3, 2014
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status
Filippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, et al.
Pathologica
|
April 9, 2026
The clinical impact of precise assessment of predictive biomarkers in gastroesophageal cancer: focus on the PD-L1 combined positive score (CPS) and tumor area positivity (TAP) systems
Alessandro Gambella, Valentina Angerilli, Federica Grillo, et al.
Journal of Gastrointestinal Oncology
|
March 11, 2017
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis
Fausto Petrelli, Rosa Berenato, Luca Turati, et al.
JAMA Oncology
|
February 9, 2023
Cancer in Transgender and Gender-Diverse Persons: A Review
Alberto Giovanni Leone, Dario Trapani, Matthew B Schabath, et al.
The Oncologist
|
April 6, 2023
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Raphael Colle, Sara Lonardi, Marine Cachanado, et al.
Oncotarget
|
September 15, 2017
Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient
Massimo Milione, Elena Ardini, Jason Christiansen, et al.
Future Oncology (London, England)
|
September 13, 2023
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer
Thierry André, Filippo Pietrantonio, Antonio Avallone, et al.
The Oncologist
|
March 13, 2020
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial
Maria Di Bartolomeo, Federica Morano, Alessandra Raimondi, et al.
The Pharmacogenomics Journal
|
February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.
Cancers
|
November 27, 2021
Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.
Page
of 33
Search research articles
Search
Showing results (81-90 of 323) with videos related to
Sort By:
Page
of 33
Plos One
|
April 3, 2014
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status
Filippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, et al.
Pathologica
|
April 9, 2026
The clinical impact of precise assessment of predictive biomarkers in gastroesophageal cancer: focus on the PD-L1 combined positive score (CPS) and tumor area positivity (TAP) systems
Alessandro Gambella, Valentina Angerilli, Federica Grillo, et al.
Journal of Gastrointestinal Oncology
|
March 11, 2017
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis
Fausto Petrelli, Rosa Berenato, Luca Turati, et al.
JAMA Oncology
|
February 9, 2023
Cancer in Transgender and Gender-Diverse Persons: A Review
Alberto Giovanni Leone, Dario Trapani, Matthew B Schabath, et al.
The Oncologist
|
April 6, 2023
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Raphael Colle, Sara Lonardi, Marine Cachanado, et al.
Oncotarget
|
September 15, 2017
Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient
Massimo Milione, Elena Ardini, Jason Christiansen, et al.
Future Oncology (London, England)
|
September 13, 2023
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer
Thierry André, Filippo Pietrantonio, Antonio Avallone, et al.
The Oncologist
|
March 13, 2020
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial
Maria Di Bartolomeo, Federica Morano, Alessandra Raimondi, et al.
The Pharmacogenomics Journal
|
February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.
Cancers
|
November 27, 2021
Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.
Page
of 33